查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1896253

個人化醫療和基因組學市場預測至2032年：按產品、技術、應用、最終用戶和地區分類的全球分析

Personalized Medicine & Genomics Market Forecasts to 2032 - Global Analysis By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics and Medical Care), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球個人化醫療和基因組學市場預計到 2025 年將達到 5,993.5 億美元，到 2032 年將達到 10,609.4 億美元，預測期內複合年成長率為 8.5%。

精準醫療是一種創新方法，它根據個人的基因組成、生活方式和環境量身定做醫療保健方案；而基因組學則專注於研究整個基因組，以了解影響健康和疾病的基因突變。結合這兩種方法，我們可以識別影響藥物反應、疾病風險和治療結果的基因差異，從而實現精準的預防、診斷和治療。與傳統的「一刀切」式醫療不同，精準醫療利用基因組學資訊來選擇最佳的治療方案和劑量，從而提高療效並減少副作用。基因組學技術的進步，例如全基因測序，使這一切成為可能，並將醫療保健轉變為更具預測性、預防性和以患者為中心的實踐。

對個人化治療的需求日益成長

個人化醫療和基因組學市場的主要驅動力是對客製化療法日益成長的需求。醫療保健正穩步從「一刀切」的治療模式轉向精準醫療，患者和臨床醫生越來越傾向於尋求根據其基因譜、疾病亞型和個別藥物反應量身定做的治療方法。這種轉變將提高治療效果，最大限度地減少不良反應，並改善患者預後。人們對基因檢測的日益關注，以及定序技術的進步，正持續推動個人化醫療從小眾方法走向主流臨床實踐。

個人化解決方案高成本

個人化醫療和基因組學的高成本仍然是限制市場成長的一大阻礙因素。先進的基因測序、生物資訊基礎設施、伴隨診斷和客製化治療都需要大量的資金投入。這些費用限制了其可近性，尤其是在發展中地區和對成本較為敏感的醫療體系中。此外，報銷難題和保險覆蓋範圍的不均衡也進一步阻礙了其普及。儘管技術成本正在逐步下降，但經濟負擔仍然是阻礙個人化醫療解決方案廣泛應用的主要障礙。

巨量資料與人工智慧的融合

巨量資料分析與人工智慧的融合為個人化醫療和基因組學市場帶來了巨大的成長機會。人工智慧驅動的工具能夠快速分析海量基因組資料集，進而改善疾病預測、藥物研發和治療方法最佳化。巨量資料平台有助於發現傳統分析方法無法檢測到的潛在遺傳模式和關聯。隨著醫療保健系統日益採用數位化基礎設施，人工智慧驅動的基因組學有望加速臨床決策，並實現可擴展的、數據驅動的個人化醫療。

資料安全和隱私風險

鑑於基因組數據的高度敏感性及其對個人隱私的深遠影響，資料安全和隱私風險對個人化醫療和基因組學市場構成嚴重威脅。資料外洩、濫用和未授權存取可能會損害患者信任，並招致監管機構的審查。嚴格的資料保護法律和合規要求增加了市場相關人員的營運複雜性。如果缺乏強大的網路安全保障和合乎倫理的資料管治，保密性問題可能會減緩基因組技術的普及應用，並限制基因組創新所必需的大規模資料共用。

新冠疫情的影響：

新冠疫情對市場產生了複雜的影響，但最終加速了市場發展。基因測序在追蹤病毒變異、疫苗研發以及了解個別患者對感染的反應方面發揮了關鍵作用。這場危機凸顯了精準醫療在複雜疾病管理中的價值，並加速了對基因組學、生物資訊學和數位醫療基礎設施的投資。然而，臨床試驗和常規診斷的短期中斷暫時減緩了市場成長動能。

預計在預測期內，生物資訊學將佔據最大的市場規模。

由於生物資訊學在管理、分析和解讀複雜基因組數據方面發揮核心作用，預計在預測期內，生物資訊學領域將佔據最大的市場佔有率。隨著定序量的不斷成長，先進的生物資訊學平台對於將原始遺傳資訊轉化為可操作的臨床見解至關重要。人工智慧驅動的分析、基於雲端的數據儲存和運算工具在研究實驗室和醫療機構中的日益普及，持續推動市場需求，使生物資訊學成為個人化醫療的基礎。

預計在預測期內，腫瘤治療領域將達到最高的複合年成長率。

預計在預測期內，腫瘤學領域將實現最高成長率，這主要得益於基因組學在癌症診斷、預後和標靶治療研發中日益廣泛的應用。癌症的遺傳複雜性決定了個人化治療方案的必要性，而精準腫瘤學與基因組學技術高度契合。癌症發生率的上升、伴隨診斷的普及以及基因療法在臨床上的應用日益廣泛，都將推動腫瘤學領域的成長，使其成為成長最快的應用領域。

佔比最大的地區：

由於醫療基礎設施不斷完善、基因組學研究舉措日益增多以及政府對精準醫療項目的支持力度加大，亞太地區預計將在預測期內佔據最大的市場佔有率。大規模的患者群體、慢性病盛行率的上升以及基因檢測可及性的提高正在推動精準醫療技術的普及。中國、日本和印度等國家正在大力投資基因組學、生物資訊學和個人化醫療，從而鞏固其在該地區的市場主導地位。

年複合成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這主要得益於其強大的技術領先地位、高昂的醫療保健支出以及對個性化醫療解決方案的早期應用。領先的基因組學公司、先進的研究機構以及完善的法規結構正在加速創新和商業化。人工智慧、巨量資料分析和精準腫瘤學的日益普及，以及有利的報銷政策，正持續推動全部區域市場的快速成長。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，對主要國家的市場規模和複合年成長率進行估算和預測（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 摘要
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球個人化醫療和基因組學市場（按產品分類）

  • 個性化醫療診斷
    • 基因檢測
    • 即時檢測
    • 基於生物標記的檢測
    • 伴隨診斷
  • 個人化醫療治療方法
    • 標靶治療
    • 數位健康與保健解決方案
    • 基於藥物基因體學的藥物
  • 醫療保健
    • 個人化營養
    • 預防醫學計劃

6. 全球個人化醫療和基因組學市場（按技術分類）

  • 基因組學
  • 生物資訊學
  • 蛋白質體學
  • 數位健康平台
  • 代謝體學
  • 表觀遺傳學

7. 全球個人化醫療和基因組學市場（按應用分類）

  • 腫瘤學
  • 感染疾病
  • 心臟病學
  • 自體免疫疾病
  • 神經病學
  • 免疫學
  • 其他用途

8. 全球個人化醫療和基因組學市場（按最終用戶分類）

  • 醫院和診所
  • 製藥和生物技術公司
  • 診斷檢查室
  • 學術和研究機構
  • 其他最終用戶

9. 全球個人化醫療和基因組學市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章 企業概況

  • Illumina, Inc.
  • Genomic Health, Inc.
  • Thermo Fisher Scientific, Inc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Novartis AG
  • Foundation Medicine, Inc.
  • Pfizer Inc.
  • Guardant Health, Inc.
  • Bristol Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Merck &Co., Inc.
  • Agilent Technologies, Inc.
  • Qiagen NV
Product Code: SMRC32941

According to Stratistics MRC, the Global Personalized Medicine & Genomics Market is accounted for $599.35 billion in 2025 and is expected to reach $1,060.94 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine is an innovative approach that tailors healthcare to an individual's genetic makeup, lifestyle, and environment, while genomics focuses on studying the entire genome to understand variations influencing health and disease. Together, they enable precise prevention, diagnosis, and treatment by identifying genetic differences that affect drug response, disease risk, and therapy outcomes. Unlike traditional "one-size-fits-all" medicine, personalized medicine uses genomic insights to select optimal treatments and dosages, improving effectiveness and reducing side effects. Genomics advances, such as whole genome sequencing, have made this possible, transforming medicine into a more predictive, preventive, and patient-centered practice.

Market Dynamics:

Driver:

Rising Demand for Tailored Therapies

The rising demand for tailored therapies is a primary driver of the personalized medicine and genomics market, as healthcare steadily moves away from blanket treatments toward precision-based care. Patients and clinicians increasingly seek therapies aligned with genetic profiles, disease subtypes, and individual drug responses. This shift improves treatment efficacy, minimizes adverse effects, and enhances patient outcomes. Growing awareness of genetic testing, coupled with advancements in sequencing technologies, continues to push personalized medicine from a niche approach into mainstream clinical practice.

Restraint:

High Costs of Personalized Solutions

High costs associated with personalized medicine and genomics remain a significant restraint on market growth. Advanced genomic sequencing, bioinformatics infrastructure, companion diagnostics, and customized therapies require substantial financial investment. These expenses limit accessibility, particularly in developing regions and cost-sensitive healthcare systems. Additionally, reimbursement challenges and uneven insurance coverage further slow adoption. While technology costs are gradually declining, the economic burden continues to hinder widespread implementation of personalized healthcare solutions.

Opportunity:

Integration of Big Data & AI

The integration of big data analytics and artificial intelligence presents a major growth opportunity for the personalized medicine and genomics market. AI-driven tools enable rapid analysis of vast genomic datasets, improving disease prediction, drug discovery, and treatment optimization. Big data platforms help uncover hidden genetic patterns and correlations that traditional analysis cannot detect. As healthcare systems increasingly adopt digital infrastructure, AI-powered genomics is set to accelerate clinical decision-making and unlock scalable, data-driven personalized care.

Threat:

Data Security and Privacy Risks

Data security and privacy risks pose a serious threat to the personalized medicine and genomics market, as genomic data is highly sensitive and deeply personal. Breaches, misuse, or unauthorized access can undermine patient trust and invite regulatory scrutiny. Strict data protection laws and compliance requirements increase operational complexity for market players. Without robust cybersecurity frameworks and ethical data governance, concerns over confidentiality may slow adoption and limit large-scale data sharing essential for genomic innovation.

Covid-19 Impact:

The COVID-19 pandemic had a mixed but ultimately accelerating impact on the market. Genomic sequencing played a critical role in tracking virus mutations, vaccine development, and understanding patient-specific responses to infection. The crisis highlighted the value of precision medicine in managing complex diseases and accelerated investments in genomics, bioinformatics, and digital health infrastructure. However, short-term disruptions in clinical trials and routine diagnostics temporarily slowed market momentum.

The bioinformatics segment is expected to be the largest during the forecast period

The bioinformatics segment is expected to account for the largest market share during the forecast period, due to its central role in managing, analyzing, and interpreting complex genomic data. As sequencing volumes increase, advanced bioinformatics platforms are essential for transforming raw genetic information into actionable clinical insights. Growing adoption of AI-driven analytics, cloud-based data storage, and computational tools across research and healthcare settings continues to fuel demand, making bioinformatics the backbone of personalized medicine.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, due to growing application of genomics in cancer diagnosis, prognosis, and targeted therapy development. Cancer's genetic complexity demands personalized treatment approaches, making precision oncology a natural fit for genomic technologies. Rising cancer prevalence, increasing use of companion diagnostics, and expanding clinical adoption of gene-based therapies are accelerating growth and positioning oncology as the fastest-growing application area.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to expanding healthcare infrastructure, rising genomic research initiatives, and increasing government support for precision medicine programs. Large patient populations, growing prevalence of chronic diseases, and improving access to genetic testing are driving adoption. Countries such as China, Japan, and India are investing heavily in genomics, bioinformatics, and personalized healthcare, strengthening the region's dominant market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong technological leadership, high healthcare spending, and early adoption of personalized medicine solutions. The presence of major genomics companies, advanced research institutions, and supportive regulatory frameworks accelerates innovation and commercialization. Increasing use of AI, big data analytics, and precision oncology, along with favorable reimbursement trends, continues to propel rapid market growth across the region.

Key players in the market

Some of the key players in Personalized Medicine & Genomics Market include Illumina, Inc., Genomic Health, Inc., Thermo Fisher Scientific, Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Novartis AG, Foundation Medicine, Inc., Pfizer Inc., Guardant Health, Inc., Bristol Myers Squibb, Bio-Rad Laboratories, Inc., Merck & Co., Inc., Agilent Technologies, Inc., and Qiagen N.V.

Key Developments:

In November 2025, Siemens Healthineers introduced Syngo Carbon 2.0, an upgraded enterprise imaging platform. The launch integrates multimodal imaging data, AI-powered workflow automation, and cloud-based collaboration, designed to streamline radiology operations and improve diagnostic accuracy across global healthcare systems.

In October 2025, Siemens Healthineers expanded its collaboration with Varian and multiple oncology centers to accelerate precision therapy solutions. The joint venture integrates imaging, radiation therapy, and AI-driven planning tools, aiming to improve cancer treatment outcomes and strengthen Siemens' leadership in oncology care.

Products Covered:

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics
  • Medical Care

Technologies Covered:

  • Genomics
  • Bioinformatics
  • Proteomics
  • Digital Health Platforms
  • Metabolomics
  • Epigenetics

Applications Covered:

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Autoimmune Diseases
  • Neurology
  • Immunology
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine & Genomics Market, By Product

  • 5.1 Introduction
  • 5.2 Personalized Medicine Diagnostics
    • 5.2.1 Genetic Testing
    • 5.2.2 Point-of-Care Testing
    • 5.2.3 Biomarker-Based Tests
    • 5.2.4 Companion Diagnostics
  • 5.3 Personalized Medicine Therapeutics
    • 5.3.1 Targeted Therapies
    • 5.3.2 Digital Health & Wellness Solutions
    • 5.3.3 Pharmacogenomics-Based Drugs
  • 5.4 Medical Care
    • 5.4.1 Personalized Nutrition
    • 5.4.2 Preventive Care Programs

6 Global Personalized Medicine & Genomics Market, By Technology

  • 6.1 Introduction
  • 6.2 Genomics
  • 6.3 Bioinformatics
  • 6.4 Proteomics
  • 6.5 Digital Health Platforms
  • 6.6 Metabolomics
  • 6.7 Epigenetics

7 Global Personalized Medicine & Genomics Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Diseases
  • 7.4 Cardiology
  • 7.5 Autoimmune Diseases
  • 7.6 Neurology
  • 7.7 Immunology
  • 7.8 Other Applications

8 Global Personalized Medicine & Genomics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Pharmaceutical & Biotechnology Companies
  • 8.4 Diagnostic Laboratories
  • 8.5 Academic & Research Institutes
  • 8.6 Other End Users

9 Global Personalized Medicine & Genomics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina, Inc.
  • 11.2 Genomic Health, Inc.
  • 11.3 Thermo Fisher Scientific, Inc.
  • 11.4 Gilead Sciences, Inc.
  • 11.5 F. Hoffmann-La Roche Ltd.
  • 11.6 Siemens Healthineers AG
  • 11.7 Novartis AG
  • 11.8 Foundation Medicine, Inc.
  • 11.9 Pfizer Inc.
  • 11.10 Guardant Health, Inc.
  • 11.11 Bristol Myers Squibb
  • 11.12 Bio-Rad Laboratories, Inc.
  • 11.13 Merck & Co., Inc.
  • 11.14 Agilent Technologies, Inc.
  • 11.15 Qiagen N.V.

List of Tables

  • Table 1 Global Personalized Medicine & Genomics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Medicine & Genomics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Medicine & Genomics Market Outlook, By Personalized Medicine Diagnostics (2024-2032) ($MN)
  • Table 4 Global Personalized Medicine & Genomics Market Outlook, By Genetic Testing (2024-2032) ($MN)
  • Table 5 Global Personalized Medicine & Genomics Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
  • Table 6 Global Personalized Medicine & Genomics Market Outlook, By Biomarker-Based Tests (2024-2032) ($MN)
  • Table 7 Global Personalized Medicine & Genomics Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
  • Table 8 Global Personalized Medicine & Genomics Market Outlook, By Personalized Medicine Therapeutics (2024-2032) ($MN)
  • Table 9 Global Personalized Medicine & Genomics Market Outlook, By Targeted Therapies (2024-2032) ($MN)
  • Table 10 Global Personalized Medicine & Genomics Market Outlook, By Digital Health & Wellness Solutions (2024-2032) ($MN)
  • Table 11 Global Personalized Medicine & Genomics Market Outlook, By Pharmacogenomics-Based Drugs (2024-2032) ($MN)
  • Table 12 Global Personalized Medicine & Genomics Market Outlook, By Medical Care (2024-2032) ($MN)
  • Table 13 Global Personalized Medicine & Genomics Market Outlook, By Personalized Nutrition (2024-2032) ($MN)
  • Table 14 Global Personalized Medicine & Genomics Market Outlook, By Preventive Care Programs (2024-2032) ($MN)
  • Table 15 Global Personalized Medicine & Genomics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 16 Global Personalized Medicine & Genomics Market Outlook, By Genomics (2024-2032) ($MN)
  • Table 17 Global Personalized Medicine & Genomics Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 18 Global Personalized Medicine & Genomics Market Outlook, By Proteomics (2024-2032) ($MN)
  • Table 19 Global Personalized Medicine & Genomics Market Outlook, By Digital Health Platforms (2024-2032) ($MN)
  • Table 20 Global Personalized Medicine & Genomics Market Outlook, By Metabolomics (2024-2032) ($MN)
  • Table 21 Global Personalized Medicine & Genomics Market Outlook, By Epigenetics (2024-2032) ($MN)
  • Table 22 Global Personalized Medicine & Genomics Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Personalized Medicine & Genomics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 24 Global Personalized Medicine & Genomics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 25 Global Personalized Medicine & Genomics Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 26 Global Personalized Medicine & Genomics Market Outlook, By Autoimmune Diseases (2024-2032) ($MN)
  • Table 27 Global Personalized Medicine & Genomics Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 28 Global Personalized Medicine & Genomics Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 29 Global Personalized Medicine & Genomics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 30 Global Personalized Medicine & Genomics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Personalized Medicine & Genomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Personalized Medicine & Genomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 33 Global Personalized Medicine & Genomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Personalized Medicine & Genomics Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 35 Global Personalized Medicine & Genomics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.